Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly's Pancreatic Enzyme Replacement Therapy Faces Advisory Committee Scrutiny

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Gastrointestinal Drugs panel's Jan. 12 review of Solpura (liprotamase) is likely to focus on robustness of efficacy results and relevant endpoints.

You may also be interested in...



Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy

Alnara hopes to leverage Lilly's prior success with recombinant insulin products.

This Little Pig-Free Product Goes To Market? Alnara's High Hopes For A PERT

Alnara claims its latest trial shows real-world effectiveness of liprotamase, formerly called Trizytek, and plans early 2010 NDA.

Pancreatic Insufficiency Drug Makers Given NDA Approval Deadline Of 2008

FDA is not removing unapproved products from the market because they are medically necessary. However, manufacturers must obtain approval of exocrine pancreatic insufficiency drugs within four years.

Related Content

Topics

UsernamePublicRestriction

Register

PS071557

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel